Kennan C. Marsh

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

Medicine, Oncology, Pharmacology +16

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 773 citations · Full text

Medicine, Oncology, Pharmacology +15

Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria

Cyril Ruwende, Seok-Kooi Khoo, Robert W. Snow et al. · Nature · 1995 · 602 citations

Life Sciences, Biology, Genetics +12

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Dale J. Kempf, Kennan C. Marsh, Jon F. Denissen et al. · Proceedings of the National Academy of Sciences · 1995 · 556 citations

Pharmacy, Pharmacokinetics, Pharmacology +16